 |
|
|
| |
Sustained Efficacy and Seroconversion With the Selective Toll-Like
Receptor 8 Agonist GS-9688 in the Woodchuck Model of Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
EASL 2018 April 19-23 Amsterdam Netherlands
Stephane Daffis,1 Jason Chamberlain,1 Jim Zheng,1 Rex Santos,1 William Rowe,1 Michael R. Mish,1 Dhivya Ramakrishnan,1 Changsuek Yon,2 Manasa Suresh,2 Stephan Menne,2 Paul Cote,2 William E. Delaney IV,1 Simon P. Fletcher,1 Richard L. Mackman1
1Gilead Sciences, Inc., Foster City, California, USA; 2Georgetown University Medical Center, Washington, DC, USA
References
1. Du J, et al. Vaccine 2010;28:6273-81; 2. Isorce N, et al. Antiviral Res 2016;130:36-45; 3. Jo J, et al. PLoS Pathog 2014;10:e1004210; 4. Lu H, et al. Clin Cancer Res 2012;18:499-509; 5. Schurich A, et al. PLoS Pathog 2013;9:e1003208; 6. Hemmi H, et al. Nat Immunol 2002;3:196-200; 7. Liu J, et al. Mol Immunol 2010;47:1083-90; 8. Fletcher S, et al. Hepatology 2012;56:820-30; 9. Menne S, et al. World J Gastroenterol 2007;13:104-24; 10. Menne S, et al. Methods Mol Med 2004;96:27-36; 11. Menne S, et al. J Hepatol 2015;62:1237-45.
|
| |
|
|
|
|
|
